- Home
- ALV vs LEGN Comparison
ALV vs LEGN Comparison
Compare ALV & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- LEGN
- Stock Information
- Founded
- ALV 1953
- LEGN 2014
- Country
- ALV Sweden
- LEGN United States
- Employees
- ALV N/A
- LEGN N/A
- Industry
- ALV Auto Parts:O.E.M.
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- LEGN Health Care
- Exchange
- ALV Nasdaq
- LEGN Nasdaq
- Market Cap
- ALV 7.6B
- LEGN 7.0B
- IPO Year
- ALV 1997
- LEGN 2020
- Fundamental
- Price
- ALV $102.08
- LEGN $31.08
- Analyst Decision
- ALV Buy
- LEGN Strong Buy
- Analyst Count
- ALV 11
- LEGN 13
- Target Price
- ALV $113.09
- LEGN $79.42
- AVG Volume (30 Days)
- ALV 746.8K
- LEGN 1.6M
- Earning Date
- ALV 04-16-2025
- LEGN 05-13-2025
- Dividend Yield
- ALV 2.75%
- LEGN N/A
- EPS Growth
- ALV 35.84
- LEGN N/A
- EPS
- ALV 8.68
- LEGN N/A
- Revenue
- ALV $10,353,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ALV N/A
- LEGN $65.96
- Revenue Next Year
- ALV $3.53
- LEGN $52.55
- P/E Ratio
- ALV $11.74
- LEGN N/A
- Revenue Growth
- ALV N/A
- LEGN 112.46
- 52 Week Low
- ALV $75.49
- LEGN $29.27
- 52 Week High
- ALV $129.38
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ALV 72.77
- LEGN 39.41
- Support Level
- ALV $93.20
- LEGN $30.25
- Resistance Level
- ALV $102.95
- LEGN $33.30
- Average True Range (ATR)
- ALV 1.88
- LEGN 1.53
- MACD
- ALV 1.17
- LEGN -0.18
- Stochastic Oscillator
- ALV 93.72
- LEGN 26.21
About ALV Autoliv Inc.
Autoliv is the global leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.